Absci Corp (ABSI)
Healthcare
Biotechnology
7.80 $
+1.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Absci Corp (ABSI)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.8% of the shares are freely tradable; institutional investors hold 72.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
72.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
12.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
87.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
25.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
169Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 13.31 | 22,550,997 | +0.8 | 03/31/2026 |
| ARK Investment Management LLC | 8.10 | 13,726,169 | +9.4 | 03/31/2026 |
| BlackRock Inc | 6.64 | 11,255,194 | -0.7 | 03/31/2026 |
| Redmile Group, LLC | 4.87 | 8,253,316 | +0.0 | 03/31/2026 |
| State Street Corp | 4.32 | 7,324,858 | +22.3 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.48 | 5,886,640 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 6.20 | 10,504,609 | +2.2 | 07/30/2026 |
| Fidelity Growth Compy Commingled Pl S | 6.12 | 10,363,639 | +0.4 | 05/31/2026 |
| ARK Genomic Revolution | 6.04 | 10,227,759 | -8.7 | 06/30/2026 |
| Fidelity Growth Company Fund | 4.67 | 7,903,567 | +9.6 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.